Home > Oncology > ESMO 2021 > Melanoma > Combining T-VEC and pembrolizumab does not significantly improve survival in advanced, unresectable melanoma

Combining T-VEC and pembrolizumab does not significantly improve survival in advanced, unresectable melanoma

Presented By
Dr Helen Gogas, National and Kapodistrian University of Athens, Greece
Conference
ESMO 2021
Trial
Phase 3, MASTERKEY-265
First and second interim analyses of the MASTERKEY-265 trial showed no significant benefit for the combination of T-VEC and pembrolizumab over pembrolizumab alone in patients with unresectable stage IIIB/IVM1c melanoma. Previous research showed that oncolytic virotherapy with talimogene laherparepvec (T-VEC) may improve the efficacy of anti-PD-1 therapy in patients with advanced melanoma by changing the tumour microenvironment [1]. In the phase 3 MASTERKEY-265 trial (NCT02263508), 692 patients with unresectable stage IIIB-IVM1c, anti-PD-1-naïve melanoma with injectable lesions were randomised 1:1 to T-VEC/pembrolizumab or placebo/pembrolizumab. T-VEC was given at ≤4x106 plaque-forming units (PFU) followed by ≤4x108 PFU 3 weeks later and every 2 weeks until dose 5, and every 3 weeks thereafter. Pembrolizumab was given intravenously 200 mg ever...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on